Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | VNN1 | O95497 | 3/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 2/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615087 | 1.00 | GSK3B (1.00) | GSK3BPTPN1VNN1GRM5MEP1A | |
| SCHEMBL6578442 | 0.92 | GSK3B (0.85) | GSK3BPTPN1VNN1GRM5GPR139 | |
| SCHEMBL8105775 | 0.85 | GSK3B (0.74) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL1712250 | 0.84 | GSK3B (0.72) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL16863084 | 0.82 | GSK3B (0.70) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL14437408 | 0.82 | GSK3B (0.70) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL10745445 | 0.82 | GSK3B (0.70) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL311049 | 0.82 | GSK3B (0.70) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL12231204 | 0.82 | GSK3B (0.70) | GSK3BVNN1GRM5CLK1DYRK1A | |
| SCHEMBL30375734 | 0.82 | GSK3B (0.70) | GSK3BVNN1GRM5CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4628163-A1 | NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4620533-A2 | ANTAGONIST COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-12383560-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4323062-B1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2025-07-23 | — | — | EP | disclosed |
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2025-03-27 | — | — | US | disclosed |
| US-5561142-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-10-01 | — | — | US | disclosed |
| US-5541197-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| US-4683232-A | N,N-DIMETHYL-P-(2,3-DIHYDRO-2-OXO-6H-1,3,4 OXADIAZIN-2-YLBENZAMIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-28 | — | — | US | disclosed |
| US-4587246-A | CARDIOTONIC | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-05-06 | — | — | US | disclosed |
| EP-0052442-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
| US-4503054-A | VASODILATORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-05 | — | — | US | disclosed |
| US-4423045-A | CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-12-27 | — | — | US | disclosed |
| EP-0052442-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383560-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | GSK3B 3110/4885PTPN1 4436/4885VNN1 1470/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | GSK3B 3003/4885PTPN1 182/4885VNN1 1642/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | GSK3B 1852/4885PTPN1 2883/4885VNN1 2165/4885 |
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | ADORA2B, RB1, ADORA3 | GSK3B 3066/4885PTPN1 3000/4885VNN1 4091/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | GSK3B 3174/4885PTPN1 862/4885VNN1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.